Xu Min, Zhao Zhongwei, Song Jingjing, Lan Xilin, Lu Siming, Chen Minjiang, Wang Zufei, Chen Weiqian, Fan Xiaoxi, Wu Fazong, Chen Li, Tu Jianfei, Ji Jiansong
Department of Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, Affiliated Lishui Hospital of Zhejiang University, The Central Hospital of Zhejiang, Lishui, Zhejiang 323000, PR China.
Department of Radiology, The Fifth Affiliated Hospital of Wenzhou Medical University, Affiliated Lishui Hospital of Zhejiang University, The Central Hospital of Zhejiang, Lishui, Zhejiang 323000, PR China.
Exp Cell Res. 2017 Feb 15;351(2):142-149. doi: 10.1016/j.yexcr.2017.01.008. Epub 2017 Jan 19.
Emerging evidence implicates an important role for myeloid-derived suppressor cells (MDSCs) in tumor growth, angiogenesis and metastasis. However, limited knowledge is known about the function of MDSCs in response to chemotherapies. In this study, we find that drug-resistant hepatocellular cancer (HCC) cells-derived conditioned medium significantly enhances the expansion and immunosuppressive function of MDSCs compared to their parental sensitive cells, which is demonstrated by increased level of arginase, nitric oxide (NO), and reactive oxygen species (ROS). Next, we reveal that drug-resistant HCC cells-derived IL-6 activated MDSCs, which is demonstrated by using an anti-IL-6 neutralizing antibody that caused a reduced MDSC immunosuppressive activity. More importantly, the depletion of MDSC via the administration of anti-Gr-1 antibody or the blockade of IL-6 signaling sensitized 5-FU-resistant H22 hepatoma to chemotherapy in the immunocompetent C57BL/6N mice. In primary human HCC, IL-6 expression levels strongly correlate with an MDSC phenotype and chemotherapy response in HCC patients. In conclusion, these results describe a role of IL-6 in the drug resistance in HCC chemotherapy and suggest that MDSC-targeting treatments may be potential therapeutic strategy for HCC chemoresistance.
新出现的证据表明,髓系来源的抑制细胞(MDSCs)在肿瘤生长、血管生成和转移中起重要作用。然而,关于MDSCs在化疗反应中的功能了解有限。在本研究中,我们发现与亲本敏感细胞相比,耐药性肝癌(HCC)细胞来源的条件培养基显著增强了MDSCs的扩增和免疫抑制功能,这通过精氨酸酶、一氧化氮(NO)和活性氧(ROS)水平的升高得以证明。接下来,我们发现耐药性HCC细胞来源的IL-6激活了MDSCs,这通过使用抗IL-6中和抗体得以证明,该抗体导致MDSC免疫抑制活性降低。更重要的是,在具有免疫活性的C57BL/6N小鼠中,通过给予抗Gr-1抗体清除MDSC或阻断IL-6信号通路可使5-氟尿嘧啶耐药的H22肝癌对化疗敏感。在原发性人类肝癌中,IL-6表达水平与HCC患者的MDSC表型和化疗反应密切相关。总之,这些结果描述了IL-6在HCC化疗耐药中的作用,并表明靶向MDSC的治疗可能是HCC化疗耐药的潜在治疗策略。
Biochem Biophys Res Commun. 2017-4-29
Int J Biochem Cell Biol. 2018-5-22
World J Gastrointest Oncol. 2024-5-15
Cell Commun Signal. 2024-2-12